PTEN and neoplasm: In contrast in two models, CTG3283 and ST3932, with activating mutations in PI3KCA but reduced PTEN protein levels monotherapy treatment with an AKTi reduced tumour growth while activity of the PI3Kαi (alpelisib) was less pronounced (Fig. 3B).